KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Net Margin (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Net Margin for 7 consecutive years, with 57.22% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 90.0% to 57.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55.68% through Dec 2025, down 311.0% year-over-year, with the annual reading at 55.68% for FY2025, 311.0% down from the prior year.
  • Net Margin hit 57.22% in Q4 2025 for Royalty Pharma, down from 72.91% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 145.37% in Q2 2021 to a low of 107.83% in Q4 2022.
  • Historically, Net Margin has averaged 50.24% across 5 years, with a median of 47.38% in 2024.
  • Biggest five-year swings in Net Margin: tumbled -11715bps in 2022 and later skyrocketed 22821bps in 2023.
  • Year by year, Net Margin stood at 9.32% in 2021, then tumbled by -1257bps to 107.83% in 2022, then soared by 212bps to 120.39% in 2023, then tumbled by -53bps to 56.32% in 2024, then increased by 2bps to 57.22% in 2025.
  • Business Quant data shows Net Margin for RPRX at 57.22% in Q4 2025, 72.91% in Q3 2025, and 15.66% in Q2 2025.